In England, 160000 individuals were estimated to be chronically infected with hepatitisCvirus(HCV)in2005andtheburdenofsevereHCV-relatedliverdisease has increased steadily for the past 15years. Direct-acting antiviral treatments can clear infection in most patients, motivating HCV elimination targets.
Summary
In England, 160000 individuals were estimated to be chronically infected with hepatitisCvirus(HCV)in2005andtheburdenofsevereHCV-relatedliverdisease has increased steadily for the past 15years. Direct-acting antiviral treatments can clear infection in most patients, motivating HCV elimination targets.
However,thecurrentburdenofHCVisunknownandnewmethodsarerequired tomonitorprogress.WeemployedaBayesianback-calculationapproach,combiningdataonsevereHCV-relatedliverdiseaseanddiseaseprogression,toreconstructhistoricalHCVincidenceandestimatecurrentprevalenceinEngland.We explicitlymodelledinfectionsoccurringinpeoplewhoinjectdrugs,thekeyrisk group,allowinginformationonthesizeofthispopulationandsurveillancedataon HCV prevalence to inform recent incidence. We estimated that there were 143000chronicinfectionsin2015(95%credibleinterval123000-161000),with 34% and 54% in those with recent and past injecting drug use, respectively.
Followingtheplannedscale-upofnewtreatments,chronicinfectionswerepredicted to fall to 113400 (94900-132400) by the end of 2018 and to 89500 (71300-108600)bytheendof2020.NumbersdevelopingsevereHCV-related liverdiseasewerepredictedtofallbyatleast24%from2015to2020.Thus,we describe a coherent framework to monitor progress using routinely collected data, which can be extended to incorporate additional data sources. Planned treatmentscale-upislikelytoachieve2020WHOtargetsforHCVmorbidity,but substantial efforts will be required to ensure that HCV testing and patient engagementaresufficientlyhigh.
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| INTRODUC TI ON
HepatitisCvirus(HCV)isablood-borneinfectionthatcausesprogressive fibrosis of the liver and can lead to cirrhosis and hepatocellular carcinoma (HCC). It has a long incubation time, with many individualsremainingasymptomaticfordecades,althoughprogressiontendstoacceleratewithage. 1, 2 Themajorityofnewinfections inEnglandoccurinpeoplewhoinjectdrugs(PWID). 3 Thesizeofthis group was estimated to be growing rapidly throughout the 1980s and1990s, 4 withover50%estimatedtobeHCVantibodypositive. 5 GrowingnumbersofpeoplewithchronicHCVinfectionarenowdevelopingsevereliverdisease,withtheburdenpredictedtoriseover the next decade. 6 However, new treatments can clear the virus in the majority of those infected, including those with advanced disease. 7, 8 Suchisthecurrentoptimismthatmanycountriesareinthe process of setting timelines for eliminating HCV as a major public health threat by 2030 or before, or incarcerated. 13 In Scotland, prevalence estimates were derived on the basis of multi-parameter evidence synthesis (MPES), which combines data from different sources and estimates prevalence in differentriskgroups.
14 Thefuturecourseoftheepidemicandimpact oftreatmentondiseaseburdenhasbeeninvestigatedthroughnaturalhistorymodelsofHCV-relateddiseaseprogression.Suchmodels typically make inferences using data on disease endpoints, which aremodelledviaback-calculationorusedtocalibratemathematical models. [15] [16] [17] Two approaches previously used in England are MPES models toestimatetheprevalenceofHCV 18, 19 andback-calculationmodels basedontrendsinsevereHCV-relatedliverdisease. 6, 20 KeylimitationsfortheMPESapproacharethatsomeofthedatasourcesare collected infrequently and information on ex-PWID is limited. In addition to the risk group/disease state structure described above, the infected population is further compartmentalized into never diagnosed, ever diagnosed and still infected, and sustained 
| MATERIAL S AND ME THODS
viral response (SVR) states, the latter being the result of successful treatment. 
| Parameterization and estimation

| Parameter estimates and model fit
| Prevalence estimates and predictions
We estimated that the number of PWID aged 15-64 in 2011 was 135000 (95% CrI: 95000-178000, rounded to nearest 1000), around44%largerthan2011/12estimatesofthenumberofpeo-plewhohadinjectedinthelastyearusedinthemodel.ThenumberofPWIDisestimatedtohavepeakedin1998at178000(95% CrI:140000-217000)anddeclinedto123000(95%CrI:84000-166000)in2015.Theincidenceofchronicinfectionisestimatedto havebeenbelow2000peryearpriorto1970,thenrisentoapeak of7100(95%CrI:6000-8400)peryearintheearly1990s,thendeclinedto4300(95%CrI:3400-5400)peryearin2015. 
| Sensitivity analyses
TheNTAestimateofthenumberofPWIDinfluencesthenumber of people with chronic infection, given the risk of infection in
PWIDandcessationrate.Ifthisinformationisomitted,thenumber ofchronicinfectionsin2015wasestimatedtobe218200(175500-252800). This is largely driven by the data on ESLD: when modelling data on HCC alone, estimates were comparable to the base model, but were far higher when modelling data on ESLD alone. 
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